Nexviazyme Clinical Trials

Diaz-Manera J, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021 Dec;20(12):1012-1026
Kishnani et al Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97Weeks. A Phase 3 Randomized Clinical Trial JAMA Neurol. 2023;80(6):558-567. doi:10.1001/jamaneurol.2023.0552

PBS Information: NEXVIAZYME. This product is not listed on the PBS. This product is funded under the Life Saving Drugs Program.

Please review full Nexviazyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.